ES2195196T3 - Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion. - Google Patents

Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion.

Info

Publication number
ES2195196T3
ES2195196T3 ES97953486T ES97953486T ES2195196T3 ES 2195196 T3 ES2195196 T3 ES 2195196T3 ES 97953486 T ES97953486 T ES 97953486T ES 97953486 T ES97953486 T ES 97953486T ES 2195196 T3 ES2195196 T3 ES 2195196T3
Authority
ES
Spain
Prior art keywords
imprint
determination
normal
restoring
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97953486T
Other languages
English (en)
Inventor
Andrew P Feinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2195196T3 publication Critical patent/ES2195196T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan composiciones y procedimientos para el diagnóstico y el tratamiento de enfermedades que están asociadas con la impronta. Tales composiciones y procedimientos son útiles para restaurar un modelo normal de impronta. Las composiciones comprenden agentes farmacológicos que están implicados en la impronta y que se pueden usar en procedimientos preventivos y terapéuticos para restaurar un modelo normal de impronta. Tales agentes pueden restaurar un modelo normal de impronta en células. Otros procedimientos de la invención incluyen medios para identificar compuestos farmacológicos que ejercen su efecto restaurando la impronta normal en cromosomas y genes con impronta anómala. Además, la invención se podría usar también para identificar nuevos compuestos que ejercen su efecto restaurando la impronta normal en tejidos enfermos que presentan una impronta anómala subyacente.
ES97953486T 1996-12-30 1997-12-29 Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion. Expired - Lifetime ES2195196T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3409596P 1996-12-30 1996-12-30

Publications (1)

Publication Number Publication Date
ES2195196T3 true ES2195196T3 (es) 2003-12-01

Family

ID=21874277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97953486T Expired - Lifetime ES2195196T3 (es) 1996-12-30 1997-12-29 Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion.

Country Status (9)

Country Link
EP (1) EP0969822B1 (es)
JP (2) JP4913270B2 (es)
AT (1) ATE235190T1 (es)
AU (1) AU5722398A (es)
CA (1) CA2276306C (es)
DE (1) DE69720283T2 (es)
DK (1) DK0969822T3 (es)
ES (1) ES2195196T3 (es)
WO (1) WO1998029108A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803195B1 (en) * 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
GB0107267D0 (en) * 2001-03-23 2001-05-16 Babraham Inst Diagnostic method for determining the methylation state of cloned embryos
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2002952944A0 (en) * 2002-11-27 2002-12-12 Human Genetic Signatures Pty Ltd Restoration of methylation states in cells
EP1641936B1 (en) 2003-06-17 2010-08-04 Human Genetic Signatures PTY Ltd. Methods for genome amplification
US7846693B2 (en) 2003-09-04 2010-12-07 Human Genetic Signatures Pty. Ltd. Nucleic acid detection assay
US8168777B2 (en) 2004-04-29 2012-05-01 Human Genetic Signatures Pty. Ltd. Bisulphite reagent treatment of nucleic acid
EP1794173B1 (en) 2004-09-10 2010-08-04 Human Genetic Signatures PTY Ltd Amplification blocker comprising intercalating nucleic acids (ina) containing intercalating pseudonucleotides (ipn)
US7833942B2 (en) 2004-12-03 2010-11-16 Human Genetic Signatures Pty. Ltd. Methods for simplifying microbial nucleic acids by chemical modification of cytosines
CA2609218C (en) 2005-05-26 2016-10-11 Human Genetic Signatures Pty Ltd Isothermal strand displacement amplification using primers containing a non-regular base
US8343738B2 (en) 2005-09-14 2013-01-01 Human Genetic Signatures Pty. Ltd. Assay for screening for potential cervical cancer
GB0607063D0 (en) * 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
US8685675B2 (en) 2007-11-27 2014-04-01 Human Genetic Signatures Pty. Ltd. Enzymes for amplification and copying bisulphite modified nucleic acids
EP2753710B1 (en) 2011-09-07 2017-01-11 Human Genetic Signatures Pty Ltd Molecular detection assay
WO2018214249A1 (zh) * 2017-05-22 2018-11-29 立森印迹诊断技术（无锡）有限公司 一种印记基因分级模型及其组成的系统和应用
JP2021524758A (ja) * 2018-05-18 2021-09-16 リセン インプリンティング ダイアグノステックス，インク．Ｌｉｓｅｎ Ｉｍｐｒｉｎｔｉｎｇ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 生検細胞サンプルによるがんを診断する方法
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN110791563B (zh) * 2018-08-01 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测甲状腺肿瘤良恶性程度的分级模型及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO1992015602A1 (en) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Cancer diagnosis and therapy
EP0627436A1 (en) * 1991-08-08 1994-12-07 TSUMURA & CO. Carcinostatic compound and production thereof
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines

Also Published As

Publication number Publication date
WO1998029108A2 (en) 1998-07-09
DE69720283D1 (de) 2003-04-30
CA2276306A1 (en) 1998-07-09
DK0969822T3 (da) 2003-07-21
DE69720283T2 (de) 2004-01-29
JP2009072197A (ja) 2009-04-09
JP4913270B2 (ja) 2012-04-11
AU5722398A (en) 1998-07-31
ATE235190T1 (de) 2003-04-15
WO1998029108A3 (en) 1999-02-18
EP0969822B1 (en) 2003-03-26
EP0969822A2 (en) 2000-01-12
CA2276306C (en) 2009-12-15
JP2001507703A (ja) 2001-06-12

Similar Documents

Publication Publication Date Title
ES2195196T3 (es) Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
BR9810062A (pt) Composição cosmética contendo um agente alvejante, bem como uso de uma fonte de água em combinação com a mesma
WO2022104136A3 (en) Methods and compositions for tauopathy diagnosis and treatment
ATE249828T1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
DE60238038D1 (de) Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
ES2104142T3 (es) Aminociclohexilamidas para utilizacion antirritmica y anestesica.
PT841912E (pt) 2-aminocarbonil-1,2-bis(metilsulfonil)-1-(substituido)-hidrazinas antitumor
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
Lerner et al. Eastern Cooperative Oncology Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma.
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
Verzé et al. Distribution of GAP‐43 nerve fibers in the skin of the adult human hand
DE69824017D1 (de) Vehikel zur gentherapie enthaltend dermales huellgewebe
Soleimani et al. RETRACTED: Evaluation of the neuroprotective effects of electromagnetic fields and coenzyme Q10 on hippocampal injury in mouse
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
EP1332756A3 (en) Compositions and methods for restoring a normal pattern of imprinting to cells
ES2138734T3 (es) Procedimiento para la preparacion de derivados de 1-(3-trialquilsililfenil)-2,2,2-trifluormetil etanona.
Osguthorpe et al. Management of xeroderma pigmentosum
Ramieri et al. Growth‐associated protein‐43 immunoreactivity in human oral mucosa in dentate subjects, in edentulous patients and after implant‐anchored rehabilitation
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
Cohen EDEMA IN MYOCARDIAL INSUFFICIENCY